{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:09:44Z","timestamp":1787004584759,"version":"build-2736575974"},"reference-count":18,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2003,11,4]],"date-time":"2003-11-04T00:00:00Z","timestamp":1067904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Transplantation"],"published-print":{"date-parts":[[2003,12]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract:<\/jats:bold>\n                    <jats:bold>Background:<\/jats:bold>\n                    Two hundred and forty cadaveric renal transplant recipients given anti\u2010thymocyte globulin (Thymoglobulin\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ) as induction immunotherapy were followed up prospectively to review safety and efficacy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    The median number of infusions was 10 [2\u201321] with a cumulative dose of 8.8\u2003mg\/kg [2.0\u201323.2\u2003mg\/kg]. During the fortnight following transplantation, 231 patients (96%) received a calcineurin inhibitor; all patients were given steroids and azathioprine or mycophenolate mofetil. At 1\u2003yr, 60% of patients were on tripletherapy, 38% on bitherapy, and 2% on monotherapy; 20% had discontinued steroids.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Tolerance was excellent with no cases of anaphylaxis. The commonest adverse event was fever (55%). Eighteen patients developed serum sickness on median day 11 [10\u201314]. Seven patients had thrombocytopenia; six patients had severe neutropenia. All of these adverse events recovered spontaneously. The overall incidence of delayed graft function was 24%.\n                  <\/jats:p>\n                  <jats:p>At 1\u2003yr patient and graft survival were 98 and 95%, respectively, and creatinine was 135\u2003\u00b1\u200343 \u03bcmol\/L. Clinically suspected and biopsy\u2010proven acute rejection were observed in 65 patients (27%) and 34 patients (14%), respectively. There were 62 non\u2010cytomegalovirus (CMV) infections (two fatal) and 81 episodes of CMV infections. Eight malignancies were reported; two possibly related to immunosuppression.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    These results demonstrate that anti\u2010thymocyte globulin has a safety profile with good tolerability and excellent efficacy.\n                  <\/jats:p>","DOI":"10.1046\/j.1399-0012.2003.00102.x","type":"journal-article","created":{"date-parts":[[2003,11,4]],"date-time":"2003-11-04T04:04:37Z","timestamp":1067918677000},"page":"539-545","source":"Crossref","is-referenced-by-count":67,"title":["Induction therapy by anti\u2010thymocyte globulin (rabbit) in renal transplantation: a 1\u2010yr follow\u2010up of safety and efficacy"],"prefix":"10.1111","volume":"17","author":[{"given":"Matthias","family":"B\u00fcchler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Hurault de","family":"Ligny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Madec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvon","family":"Lebranchu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The French Thymoglobuline Pharmacovigilance Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,11,4]]},"reference":[{"key":"e_1_2_21_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00075200-200112000-00009"},{"key":"e_1_2_21_3_2","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1681\/ASN.V8111771","article-title":"Effect of anti\u2010lymphocyte induction therapy on renal allograft survival: a meta\u2010analysis","volume":"8","author":"Szczech LA","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_21_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-10-199805150-00004"},{"key":"e_1_2_21_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.3.711"},{"key":"e_1_2_21_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199711270-00010"},{"key":"e_1_2_21_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200102150-00021"},{"key":"e_1_2_21_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.1993.tb00738.x"},{"key":"e_1_2_21_9_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1399-0012.1997.tb00803.x","article-title":"Sequential biological immunosuppression. Induction therapy with rabbit antithymocyte globulin","volume":"11","author":"Guttmann RD","year":"1997","journal-title":"Clin Transplant"},{"key":"e_1_2_21_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200003150-00021"},{"key":"e_1_2_21_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(99)00975-6"},{"key":"e_1_2_21_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_21_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199904150-00013"},{"key":"e_1_2_21_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199807150-00005"},{"key":"e_1_2_21_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200011150-00015"},{"key":"e_1_2_21_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2002.020109.x"},{"key":"e_1_2_21_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109270-00012"},{"key":"e_1_2_21_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(99)00992-6"},{"key":"e_1_2_21_19_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2001.10204.x"}],"container-title":["Clinical Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1399-0012.2003.00102.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1399-0012.2003.00102.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1399-0012.2003.00102.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T02:58:15Z","timestamp":1734145095000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1399-0012.2003.00102.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,11,4]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["10.1046\/j.1399-0012.2003.00102.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1399-0012.2003.00102.x","archive":["Portico"],"relation":{},"ISSN":["0902-0063","1399-0012"],"issn-type":[{"value":"0902-0063","type":"print"},{"value":"1399-0012","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,11,4]]}}}